Johnson & Johnson

Employees 2013: 128,100
Employees 2012: 126,600
% Change: +1.18
Revenues 2013: $71.31 billion
Revenues per employee 2013: $556,690

Half the companies on the list saw small increases in employment over the course of 2013 and Johnson & Johnson ($JNJ) was one of them, a bit surprising given how dynamic a year it was for J&J. While it has the second most employees after Novartis ($NVS), it managed to generate a lot of revenue per employee, ranking third, behind Roche ($RHHBY) and Merck ($MRK).

Last year was Alex Gorsky's first full year as CEO, and he put his imprimatur on the company. He masterminded growth in the pharma division with expansions in emerging markets and growing sales of a number of key drugs like rheumatoid arthritis med Remicade as well as newer offerings like the anti-inflammatory Stelara and prostate cancer therapy Zytiga.

The company continued on its roll for drug approvals with products like the breakthrough drug Imbruvica (ibrutinib), which it developed with Pharmacyclics ($PCYC). It won FDA approval in November to treat a rare form of lymphoma. It also got a 19-0 panel recommendation for its potential blockbuster, simeprevir, for treating some forms of hepatitis C. And throughout the year, it announced a series of investments in early stage efforts that will lay the groundwork for later years.

The company has a sizable medical device business and decided last year to trim that back by unloading its Ortho Clinical Diagnostics unit. It got that done in the first quarter of 2014, a decision that should affect its employee count and revenues for this year. Carlyle Group agreed to take the unit for about $4 billion.

For more:
J&J, Pharmacyclics get CLL approval for Imbruvica
Report: J&J wants Carlyle to snatch up its Ortho Clinical Diagnostics arm
J&J to pay $2.2B to wrap up long-standing Risperdal marketing probe
J&J issue in South Korea reminiscent of OTC problems here

Johnson & Johnson
Read more on

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.